Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Outlook In 108th Congress: How Much Will Lott Allot To Bill?

Executive Summary

The prospects for a Medicare prescription drug benefit in the next Congress hinge on the incoming Senate leadership's ability to negotiate long-standing divisions within the party about how much funding to commit to the program

You may also be interested in...



PBM Rebates Saved 3%-9% For Federal Employee Health Program – GAO

Prescription drug rebates passed through to health plans by PBMs reduced annual spending on drugs up to 9% in a General Accounting Office study of Federal Employee Health Benefit plans

PBM Rebates Saved 3%-9% For Federal Employee Health Program – GAO

Prescription drug rebates passed through to health plans by PBMs reduced annual spending on drugs up to 9% in a General Accounting Office study of Federal Employee Health Benefit plans

PhRMA Plans PR “Offense” In 2003 To Support Effort To Remove Access Issue

PhRMA's reconstituted public affairs program will devote half of its time and staff in 2003 to telling positive stories about the industry

Related Content

UsernamePublicRestriction

Register

PS040769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel